Last reviewed · How we verify
APD421
APD421 is a selective antagonist of the neurokinin-1 (NK1) receptor that blocks substance P signaling in the chemoreceptor trigger zone and vomiting center.
APD421 is a selective antagonist of the neurokinin-1 (NK1) receptor that blocks substance P signaling in the chemoreceptor trigger zone and vomiting center. Used for Chemotherapy-induced nausea and vomiting (CINV), Postoperative nausea and vomiting (PONV).
At a glance
| Generic name | APD421 |
|---|---|
| Sponsor | Acacia Pharma Ltd |
| Drug class | NK1 receptor antagonist |
| Target | NK1 receptor (neurokinin-1 receptor) |
| Modality | Small molecule |
| Therapeutic area | Oncology / Anesthesia |
| Phase | Phase 3 |
Mechanism of action
APD421 crosses the blood-brain barrier to antagonize NK1 receptors, which are involved in nausea and vomiting pathways. By blocking substance P, a key neurotransmitter in emetic signaling, it prevents both chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV). This mechanism complements 5-HT3 antagonists and corticosteroids used in antiemetic regimens.
Approved indications
- Chemotherapy-induced nausea and vomiting (CINV)
- Postoperative nausea and vomiting (PONV)
Common side effects
- Headache
- Dizziness
- Constipation
- Fatigue
Key clinical trials
- European Phase III Study of APD421 in PONV (PHASE3)
- Mass-balance Study of [14C]-APD421 in Healthy Volunteers (PHASE1)
- Phase IIIb Study of APD421 in Combination as PONV Prophylaxis (PHASE3)
- Phase II Dose-ranging Study of APD421 in PONV (PHASE2)
- US Phase III Study of APD421 in PONV (PHASE3)
- Study of APD421 as PONV Treatment (Prior Prophylaxis) (PHASE3)
- Study of APD421 as PONV Treatment (no Prior Prophylaxis) (PHASE3)
- Thorough QT Study of Intravenous Amisulpride (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- APD421 CI brief — competitive landscape report
- APD421 updates RSS · CI watch RSS
- Acacia Pharma Ltd portfolio CI